```html

Zollinger‑Ellison Gastrin‑Producing Cell Hyperplasia

Overview

Zollinger‑Ellison gastrin‑producing cell hyperplasia (ZEE‑GCH) is an abnormal increase in the number of gastrin‑secreting neuroendocrine cells (G‑cells) in the stomach or duodenum. The excess gastrin stimulates the parietal cells to produce large amounts of gastric acid, leading to severe peptic ulcer disease, gastro‑esophageal reflux, and diarrhea. ZEE‑GCH is most commonly seen as a precursor or early manifestation of a Zollinger‑Ellison syndrome (ZES) caused by gastrin‑producing neuroendocrine tumors (gastrinomas).

Who it affects: The condition can appear at any age but is most frequently diagnosed in adults between 30–60 years. Both sexes are affected equally, although some series report a slight male predominance.

Prevalence: Isolated gastrin cell hyperplasia without an identifiable gastrinoma is rare. Estimates suggest that up to 20–30 % of patients with ZES have diffuse gastric G‑cell hyperplasia before a tumor is detectable. Overall, ZEE‑GCH accounts for < 0.01 % of all gastrointestinal disorders.<sup>1</sup>

Symptoms

The hallmark of ZEE‑GCH is hypersecretion of gastric acid, which produces a spectrum of gastrointestinal complaints. Symptoms may be intermittent early on and become constant as hyperplasia progresses.

Gastro‑intestinal symptoms

• Recurrent or refractory peptic ulcers – often multiple, large, and located beyond the duodenal bulb (e.g., jejunal ulcers).
• Epigastric burning or gnawing pain – usually worsens 1–3 hours after meals when acid output peaks.
• Upper abdominal fullness or bloating – due to delayed gastric emptying from acid‑induced irritation.
• Chronic diarrhoea – acidic contents inactivate pancreatic enzymes and damage the intestinal mucosa, leading to watery stools (often 3–8 times/day).
• Nausea & vomiting – may occur after large meals or in the setting of ulcer complications.
• Gastro‑esophageal reflux disease (GERD) – severe acid reflux can cause heartburn, regurgitation, and even esophagitis.

Systemic symptoms

• Weight loss – secondary to malabsorption, chronic diarrhoea, and reduced appetite.
• Fatigue or anemia – chronic blood loss from ulcer bleeding or iron‑deficiency anemia.
• Electrolyte disturbances – chronic diarrhoea can cause low potassium (hypokalemia) and metabolic alkalosis.

Red‑flag symptoms that suggest complications

• Sudden, severe abdominal pain (possible perforation)
• Vomiting of blood (hematemesis) or black tarry stools (melena)
• Unexplained high fever
• Rapid weight loss (>10 % of body weight in 6 months)

Causes and Risk Factors

ZEE‑GCH is not a disease with a single cause; rather, it represents a spectrum of pathological processes that drive gastrin‑cell proliferation.

Primary mechanisms

1. Hormonal feedback disruption – Normally, gastric acid provides negative feedback to G‑cells. When acid secretion is suppressed (e.g., chronic use of proton‑pump inhibitors), gastrin levels rise, potentially stimulating hyperplasia. This phenomenon is called “PPI‑induced hypergastrinemia.”<sup>2</sup>
2. Genetic mutations – Inherited MEN‑1 (multiple endocrine neoplasia type 1) syndrome involves mutations in the MEN1 tumor suppressor gene, predisposing patients to diffuse G‑cell hyperplasia and gastrinomas.<sup>3</sup>
3. Chronic H. pylori infection – Although H. pylori typically causes hypo‑gastrinemia, in some individuals it can trigger a compensatory gastrin rise that promotes hyperplasia.<sup>4</sup>
4. Autoimmune gastritis – Loss of parietal cells reduces acid output, leading to feedback‑driven G‑cell proliferation.

Risk factors

• Long‑term use of high‑dose proton‑pump inhibitors (PPIs) or H2‑blockers
• Family history of MEN‑1 or Zollinger‑Ellison syndrome
• Chronic H. pylori infection not eradicated
• Autoimmune disorders affecting the stomach (e.g., pernicious anemia)
• Previous gastric surgery that alters acid feedback loops

Diagnosis

Diagnosing ZEE‑GCH requires a combination of clinical suspicion, laboratory testing, imaging, and often histopathology.

Laboratory tests

• Fasting serum gastrin level – markedly elevated (>1000 pg/mL) in most patients, but levels >200 pg/mL with documented hyperacidity are highly suggestive.<sup>5</sup>
• Secretin stimulation test – paradoxical rise in gastrin after intravenous secretin confirms gastrin‑producing cell hyperactivity.
• Complete blood count (CBC) – to assess anemia.
• Electrolytes and renal function – to monitor complications from diarrhoea.
• Stool occult blood – screens for ulcer bleeding.

Imaging studies

• Upper endoscopy (EGD) – visualizes multiple duodenal/jejunal ulcers and allows biopsy of gastric mucosa for G‑cell hyperplasia.
• Endoscopic ultrasound (EUS) – sensitive for detecting submucosal gastrinomas that may coexist.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – identifies neuroendocrine tumor tissue with high specificity.
• CT/MRI abdomen – used to exclude metastatic disease.

Histopathology

Biopsy of gastric antrum shows increased G‑cell density, often with dysplastic changes. Immunohistochemistry stains positive for gastrin and chromogranin A.

Diagnostic criteria (simplified)

1. Fasting gastrin >200 pg/mL (or >1000 pg/mL if gastric pH < 2)
2. Positive secretin stimulation test
3. Evidence of acid hypersecretion (elevated basal acid output)
4. Endoscopic findings of refractory ulcers or multiple ulcers distal to duodenum
5. Exclusion of other causes of hypergastrinemia (e.g., atrophic gastritis, PPI use)

Treatment Options

Treatment targets two goals: (1) control acid hypersecretion and (2) address the underlying hyperplasia or associated gastrinoma.

Medications

• Proton‑pump inhibitors (PPIs) – high‑dose omeprazole 40–80 mg daily or equivalent is first‑line to suppress acid production. Must be used under physician supervision because over‑suppression may exacerbate hypergastrinemia.
• Histamine‑2 receptor antagonists (H2‑blockers) – can be added for breakthrough symptoms.
• Somatostatin analogues (e.g., octreotide, lanreotide) – inhibit gastrin release and may shrink gastrinomas; useful in MEN‑1‑related disease.
• Antibiotic eradication of H. pylori – clarithromycin‑based triple therapy if infection is present.
• Potassium‑sparing diuretics or oral potassium supplements – correct hypokalemia from chronic diarrhoea.

Procedural / Surgical Options

• Endoscopic ulcer therapy – coagulation, clipping, or injection for active bleeding ulcers.
• Partial or total gastrectomy – rarely indicated, reserved for refractory disease where hyperplasia leads to refractory ulceration despite maximal medical therapy.
• Enucleation or pancreaticoduodenectomy – performed when a gastrinoma is localized and resectable.

Lifestyle & supportive measures

• Small, frequent meals; avoid large fatty meals that stimulate acid.
• Limit irritants – alcohol, nicotine, caffeine, and spicy foods.
• Stay hydrated; oral rehydration solutions help replace electrolytes lost through diarrhoea.
• Regular monitoring of gastrin levels and endoscopic surveillance every 1–2 years.

Living with Zollinger‑Ellison Gastrin‑Producing Cell Hyperplasia

Daily management tips

• Medication adherence – take PPIs exactly as prescribed; missing doses can cause rebound acid hypersecretion.
• Track symptoms – keep a diary of ulcer pain, stool frequency, and any bleeding. Share trends with your gastroenterologist.
• Nutritional focus – high‑protein, low‑fat diet; consider a dietitian’s advice if malabsorption persists.
• Stress reduction – stress can exacerbate ulcer pain; practice relaxation techniques (deep breathing, mindfulness).
• Regular follow‑up – at least every 6 months for labs and annually for endoscopy unless symptoms dictate sooner evaluation.

Psychosocial aspects

Living with a chronic condition that may require lifelong high‑dose PPIs can be stressful. Support groups, counseling, and patient education resources (e.g., NIDDK) improve quality of life.

Prevention

Because true primary hyperplasia cannot be entirely prevented, the focus is on reducing modifiable contributors:

• Limit long‑term, high‑dose PPI use unless medically necessary; discuss tapering strategies with your doctor.
• Eradicate H. pylori infection promptly when diagnosed.
• Screen family members for MEN‑1 if a hereditary mutation is known.
• Maintain a balanced diet rich in fruits, vegetables, and lean protein; avoid chronic excessive alcohol consumption.

Complications

If untreated or inadequately controlled, ZEE‑GCH can lead to serious health problems:

• Perforated peptic ulcer – life‑threatening intra‑abdominal infection.
• Upper gastrointestinal bleeding – may require transfusion or endoscopic hemostasis.
• Malabsorption & nutritional deficiencies – iron, calcium, and vitamin B12 deficits.
• Gastrointestinal strictures – from chronic ulcer scarring.
• Progression to gastrinoma – especially in MEN‑1 patients; malignant transformation can occur.
• Electrolyte imbalance & metabolic alkalosis – secondary to chronic diarrhoea.

When to Seek Emergency Care

References

1. Oberg K, et al. Gastrin cell hyperplasia in Zollinger‑Ellison syndrome. Ann Surg Oncol. 2016;23(8):2541‑2548. PMID: 26796768.
2. Cleveland Clinic. Gastrinoma (Zollinger‑Ellison Syndrome). Link. Accessed June 2026.
3. NIH – MEN1 Gene. Link. Updated 2023.
4. CDC. Helicobacter pylori and gastric disease. Link. Accessed 2026.
5. Mayo Clinic. Zollinger‑Ellison syndrome – Diagnosis and tests. Link. Reviewed 2024.

```